Correlation between PTEN expression and PI3K/Akt signal pathway in endometrial carcinoma

Abstract

In order to investigate the role of the PTEN expression in carcinogenesis and development of endometrial carcinoma and clarify whether and how PTEN and PI3K/Akt pathway relate to endometrial carcinoma, the expression of PTEN and phospho-Akt was detected by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) methods and Western-blot from 24 cases of endometrial carcinoma, 10 cases of endometrial atypical hyperplasia, 10 cases of endometrial hyperplasia, and 10 cases of normal endometrium. SP immunohistochemical methods were used to measure levels of PTEN protein expression in following 5 study groups: 31 cases of endometrium in proliferative phase, 30 cases of endometrium in secretory phase, 71 cases of endometrial hyperplasia, 25 cases of atypical hyperplasia and 73 cases of endometrial carcinoma. Immunostaining score of PTEN was 3.39±0.15 in proliferative phase, 1.90±0.21 in secretory phase, 3.34±0.29 in endometrial hyperplasia, 0.62±0.11 in atypical hyperplasia, and 0.74±0.19 in endometrial carcinoma, respectively. PTEN mRNA relative value in normal endometrium, endometrial hyperplasia, endometrial atypical hyperplasia, and endometrial carcinoma was 2.45±0.51, 2.32±0.32, 0.46±0.11, and 0.35±0.13 respectively. The expression levels of PTEN mRNA and protein in patients with endometrial carcinoma and atypical hyperplasia were significantly lower than in those of proliferative phase and with endometrial hyperplasia. The level of PTEN expression in patients with endometrial carcinoma was significantly related to tissue type (P<0.005), differentiation (P<0.05) and clinical stage (P<0.05), but not to depth of myometrium invasion (P>0.05). Western blot analysis revealed that Phospho-Akt level in PTEN negative cases was significantly higher, and there was a negative correlation between PTEN and phospho-Akt (r=−0.8973, P<0.0001). It was suggested that loss of PTEN expression was an early event in endometrial tumorigenesis. The phosphorylation of Akt induced by the loss of PTEN took part in the tumorigenesis and development of endometrial carcinoma.

Keywords

endometrial neoplasm / PTEN / Akt / immunohistochemistry

References

[1] BorubanM.C., AltundagK., KilicG.S., et al. . From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures. Eur J Cancer Prev, 2008, 17(2): 133-138

[2] ShangY.. Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat Rev Cancer, 2006, 6(5): 360-368

[3] Llobet D, Pallarés J, Yeramian A, et al. Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutical view points. J Clin Pathol, 2008, Oct 31 [Epub ahead of print]

[4] LiL., RossA.H.. Why is PTEN an important tumor suppressor?. J Cell Biochem, 2007, 102(6): 1368-1374

[5] HayesM.P., WangH., Espinal-WitterR., et al. . PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res, 2006, 12(20): 5932-5935

[6] MutterG.L., LinM.C., FitzgeraldJ.T., et al. . Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst, 2000, 92: 924-931

[7] OdaK., StokoeD., TaketaniY., et al. . High frequency of coexistent mutations of PI3K and PTEN genes in endometrial carcinoma. Cancer Res, 2005, 65(23): 10 669-10 673

[8] VelascoA., BussagliaE., PallaresJ., et al. . PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Hum Pathol, 2006, 37(11): 1465-1472

[9] Dubrovska A, Kim S, Salamone RJ, et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A, 2008, Dec 30. [Epub ahead of print]

[10] RychahouP.G., KangJ., GulhatiP., et al. . Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci U S A, 2008, 105(51): 20 315-20 320

[11] AlbitarL., PickettG., MorganM., et al. . Models representing type I and type II human endometrial cancers: Ishikawa H and Hec50co cells. Gynecol Oncol, 2007, 106(1): 52-64

[12] InabaF., KawamataH., TeramotoT., et al. . PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma. Oncol Rep, 2005, 13(1): 17-24

[13] Guzeloglu-KayisliO., KayisliU.A., Al-RejaalR., et al. . Regulation of PTEN (phosphatase and tensin homolog deleted on chromosome 10) expression by estradiol and progesterone in human endometrium. J Clin Endocrinol Metab, 2003, 88(10): 5017-5026

[14] HechtJ.L., MutterG.L.. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol, 2006, 24(29): 4783-4791

[15] PratJ., GallardoA., CuatrecasasM., et al. . Endometrial carcinoma: pathology and genetics. Pathology, 2007, 39(1): 72-87

[16] GründkerC., GünthertA.R., EmonsG., et al. . Hormonal heterogeneity of endometrial cancer. Adv Exp Med Biol, 2008, 630: 166-188

[17] CarneroA., Blanco-AparicioC.. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets, 2008, 8(3): 187-198

[18] HartmannW., Digon-SöntgerathB., KochA., et al. . Phosphatidylinositol 3′-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Clin Cancer Res, 2006, 12(10): 3019-3027